

Iron(II)-catalyzed intermolecular aziridination of alkenes employing hydroxylamine derivatives as clean nitrene sources

Georgina Kirby, Laurence Grimaud, Maxime R. Vitale, Guillaume Prestat*, Farouk Berhal*.

Table of Contents


I. General Information	2
II. Preparation of reagents and general procedures	2
Synthesis of hydroxylamine derivatives:	2
Preparation of Pybox ligand L2:	3
General procedure for iron aziridination reaction:	4
Large scale experiment:	5
Preparation of deuterated styrenes:	5
III. Optimization of reaction conditions	7
IV. Characterization of compounds	14
V. Copy of ¹H and ¹³C NMR spectra	25

The suspension was left to stir for 1-2 hours (reaction was followed by TLC) until full consumption of tosyl chloride. The reaction mixture was then quenched with an aqueous 1 M HCl solution (20 mL) and the aqueous phase was extracted with ethyl acetate. The organic phase was collected and washed twice more with 1 M HCl (20 mL) until the aqueous phase was pH 2-3. The combined acidic aqueous phases were extracted once more with ethyl acetate (20 mL). The combined organic phases were then dried over MgSO₄ and concentrated under reduced pressure forming a slightly yellow solid. The solid was washed with cold DCM to afford a white/slightly yellow solid (1.1 g, 75 %). Analytical data in accordance to the literature.¹

General procedure for acylation of *N*-tosyl hydroxylamine:

To a solution of *N*-tosyl hydroxylamine (1 equiv.) in DCM (C = 0.2 M) under argon at 0 °C, triethylamine (1.1 equiv.) was added in one portion. The solution was stirred for 5 mn until all solids were dissolved. A solution of acyl chloride (1 equiv.) in DCM was slowly added dropwise to the solution containing the hydroxylamine at 0 °C. The reaction was left to stir for 1 h allowing the reaction to warm to room temperature. The mixture was then quenched with an aqueous saturated NH₄Cl solution and the aqueous phase was extracted with DCM (3 times). The organic phases were combined, dried over MgSO₄ and concentrated under reduced pressure. The crude solid residue was purified by silica gel flash column chromatography using cyclohexane/ethyl acetate (100:0 to 85:15) as eluent to afford the product as a white solid.

Preparation of Pybox ligand L2:



In a round bottom flask was placed at 0 °C the 2-amino-2-methyl-1-propanol (1.64 mL, 17.16 mmol, 3.5 equiv.) and NEt₃ (3.407 mL, 24.51 mmol, 5 equiv.) in DCM (16.5 mL) under an argon atmosphere. Then, a solution of pyridine dicarbonyl dichloride (1 g, 4.90 mmol, 1 equiv.) in DCM (8 mL) was added dropwise and the resulting solution was stirred for 16 h at room temperature. The reaction was washed with cold water (20 mL) and the aqueous phase was extracted with DCM (3 x 20mL). The combined organic phases were further washed with water (20 mL) and brine (20 mL). The organic phase was dried over MgSO₄ and concentrated under reduced pressure to afford the product **A** as a white solid which was used directly in the next step. In a round bottom flask, SOCl₂ (1.57 mL, 21.61 mmol, 6 equiv.) was added to a solution of 2-*N*,6-*N*-bis(1-hydroxy-2-methylpropan-2-yl)pyridine-2,6-dicarboxamide product **A** (1.11

g, 3.60 mmol, 1 equiv.) in toluene (14.4 mL, C = 0.25 M) under argon. The reaction was stirred under reflux for 16 h. The reaction was allowed to cool to 0 °C, then washed with saturated aqueous NaHCO₃ (20 mL). The aqueous phase was extracted with ethyl acetate (3 x 20 mL) and the combined organic phases were dried over MgSO₄ and concentrated under reduced pressure to afford the chlorinated product analogue of **A** as a yellow oil which was used directly in the next step. The oil residue was placed in a round bottom flask with anhydrous THF (22 mL, C = 0.2 M) and cooled at 0 °C. Then, NaH (866 mg, 21.70 mmol, 5 equiv.) was added portion-wise and the reaction was left to stir overnight at room temperature (monitored by TLC until the starting material was fully consumed). The reaction mixture was filtered through a pad of celite[®], concentrated under reduced pressure and purified using silica gel flash column chromatography (cyclohexane/ethyl acetate/methanol from 50:50:0 to 0:90:10) to give the PyBox ligand **L2** as a slightly yellow solid (486 mg, 41 %).

General procedure for iron aziridination reaction:


Procedure A: Aziridination for styrene derivatives:

The iron(II) acetate (0.027 mmol) and PyBox ligand **L2** (0.027 mmol) were placed in a sealed tube under argon. ACN (0.5 mL) was added to the tube and the suspension was stirred at room temperature for 10 mn. Then, the *N*-(acyloxy)-4-methylbenzenesulfonamide (0.27 mmol) substrate was added to the solution followed by the alkene partner (0.68 mmol) and ACN (0.9 mL). The tube was immediately sealed and stirred at 70 °C for 18 h. The reaction was quenched with a saturated aqueous solution of NaHCO₃, the aqueous phase was extracted with DCM (3x 20 mL). The combined organic phases were dried over MgSO₄ and concentrated under reduced pressure. The crude residue was purified by silica gel flash column chromatography (eluent: cyclohexane/ethyl acetate from 100:0 to 80:20) to afford the corresponding styryl aziridine.

Procedure B: Aziridination for alkyl alkenes:

The iron(II) triflate (0.02 mmol) and PyBox ligand **L2** (0.02 mmol) were placed in a sealed tube under argon. HFIP (0.5 mL) was added to the tube and the suspension was stirred at room temperature for 10 mn. Then, the *N*-(acyloxy)-4-methylbenzenesulfonamide (0.2 mmol) was added to the solution followed by the alkyl partner (0.5 mmol) and HFIP (0.5 mL). The tube was immediately sealed and placed at 50 °C to stir for 18 h. The reaction was quenched with a saturated aqueous solution of NaHCO₃, the aqueous phase was extracted using DCM (3x 20 mL). The combined organic phases were dried over MgSO₄ and concentrated under reduced pressure. The crude residue was purified by silica gel flash column chromatography (eluent: cyclohexane/ethyl acetate from 100:0 to 80:20) to afford the corresponding alkyl aziridine.


Large scale experiment:



In a round bottom flask, $\text{Fe}(\text{OAc})_2$ (26 mg, 0.15 mmol, 0.05 equiv.) and Pybox ligand **L2** (40 mg, 0.15 mmol, 0.05 equiv.) were placed under argon in 15 mL of ACN ($C = 0.2$ M). The suspension was stirred at room temperature for 10 mn, then substrate **1b** (800 mg, 3 mmol, 1 equiv.) was added followed by styrene (0.85 mL, 7.40 mmol, 2.5 equiv.) and the flask was sealed and stirred at 70 °C for 18 h. The reaction was quenched with a saturated aqueous NaHCO_3 solution and the aqueous phase was extracted with DCM (3x 30 mL). The combined organic phases were dried over MgSO_4 and concentrated under reduced pressure. The crude residue was purified by silica gel flash column chromatography (eluent: cyclohexane/ethyl acetate from 100:0 to 80:20) to afford 720 mg (89 % yield) of tosylaziridine **3a** as a white solid. The aqueous phases were acidified to pH 1-2 using a 1 M aqueous HCl solution then extracted with DCM (3x 30 mL). The combined organic phases were dried over MgSO_4 and concentrated under reduced pressure to afford 225 mg (75 % yield) of pivalic acid as a white solid.

Preparation of deuterated styrenes:

Preparation of (*E*)-2a-D styrene:




In a round bottom flask, to a solution of (*E*)-styryl-boronic acid (300 mg, 2.03 mmol, 1 equiv.) in acetonitrile (10.14 mL, $C = 0.2$ M) at room temperature was added NBS (433 mg, 2.43 mmol, 1.2 equiv.) in one portion. The reaction mixture was stirred vigorously for 2 h until complete consumption of boronic acid (monitored by TLC). The solution was then washed with an aqueous saturated $\text{Na}_2\text{S}_2\text{O}_5$ solution (20 mL) and the aqueous phase was extracted with pentane (3 x 20 mL). The combined organic layers were then washed with water (20 mL) dried over MgSO_4 and concentrated under reduced pressure to give (*E*)-2-bromostyrene as a yellow oil (240 mg, 65 %) without further purification.

In a round bottom flask, to a solution of (*E*)-2-bromostyrene (240 mg, 1.11 mmol, 1 equiv.) in anhydrous diethyl ether (5.3 mL, $C = 0.2$ M) at -78 °C was added carefully a solution of *t*-BuLi ($C = 1.6$ M in hexanes) (1.57 mL, 2.51 mmol, 2.25 equiv.) within a minute. The solution was

stirred at $-78\text{ }^{\circ}\text{C}$ for 1 h then methanol- d_4 (4.25 mL, 105 mmol, 94 equiv.) was added. The solution was allowed to warm to room temperature over 2 h, then stirred at room temperature for another 1 h. The reaction mixture was washed with an aqueous saturated NH_4Cl solution (20 mL) and the aqueous phase was extracted with diethyl ether (3 x 20 mL). The combined organic phases were washed with brine (20 mL) and dried over MgSO_4 . The solvent was removed under reduced pressure without heating until approx. 5-10 mL of solvent was left over. Careful evaporation using a flow of air yielded (*E*)-2-deuterostyrene (**(*E*)-2a-D**) as a colorless oil (53 mg, 45 % yield, 100 % deuterated).

Preparation of (*Z*)-2a-D styrene:



In a round bottom flask, phenylacetylene (1.65 mL, 15 mmol, 1 equiv.) was added slowly to *n*-butyllithium ($C = 1.6\text{ M}$ in hexanes) (12.2 mL, 19.53 mmol, 1.3 equiv.) over 15 minutes at $0\text{ }^{\circ}\text{C}$. The resulting suspension was stirred at $0\text{ }^{\circ}\text{C}$ for 1 hour, then D_2O (1.11 mL, 41.6 mmol, 2.8 equiv.) was added slowly. The reaction was stirred at room temperature overnight, then passed through a pad of MgSO_4 washed with pentane and carefully concentrated under reduced pressure, without heating to afford phenylacetylene- d_1 as a colorless liquid. In a round bottom flask, zirconocene hydrochloride (Schwartz' reagent) (1.1 g, 4.27 mmol, 1.1 equiv.) was added in two equal portions to a solution of phenylacetylene- d_1 (400 mg, 3.9 mmol, 1 equiv.) in DCM (10 mL, $C = 0.4\text{ M}$) at $0\text{ }^{\circ}\text{C}$. After stirring at room temperature in the dark for 2 h, water (0.55 mL, 30.75 mmol, 8 equiv.) was added and the reaction was stirred for a further 2 h. The reaction was dried over MgSO_4 , filtered and concentrated under reduced pressure to approx. 2 mL. Pentane (20 mL) was then added and the resulting solution was passed through a silica pad. Then the solid was washed with pentane and the filtrate was concentrated under reduced pressure (no heating) to afford (*Z*)-2-deuterostyrene (**(*Z*)-2a-D**) as a pale-yellow oil (367 mg, 90 % yield, 100 % deuterated).

III. Optimization of reaction conditions

Optimization on styrene 2a:







Table 1.

Entry	Ligand	Yield
1	---	25 %
2	Phenanthroline (20 mol%)	47 %
3	2,2':6',2''-Terpyridine	13 %
4	2,2'-bipyridine (20 mol%)	trace
5		trace
6		trace
7	Tetraphenylporphyrin	7 %
8		80 %




Table 2.

Entry	1 (equiv.)	2 (equiv.)	Fe Cat (10 mol%)	Ligand	T °C	Yield
1	1	2.5	Fe(OTf) ₂		70 °C	23 %
2	1	2.5	Fe(Cl) ₂		70 °C	47 %
3	1	2.5	Fe(Br) ₃		70 °C	50 %
4	1	2.5	---	---	70 °C	0 %
5	1	2.5	Cu(OAc) ₂		70 °C	trace
6	1	2.5	CuI		70 °C	trace
7	1	2.5	Fe(OAc) ₂ (5 mol%)	 (5 mol%)	70 °C	78 %
8	1	2.5	Fe(OAc) ₂		50 °C	76 %
9	1	2	Fe(OAc) ₂		70 °C	77 %
10	1	1.5	Fe(OAc) ₂		70 °C	63 %
11	2	1	Fe(OAc) ₂		70 °C	58 %




Table 3.

Entry	Ligand	Solvent	Yield
1		ACN	80 %
2		DCM/ACN 9:1	60 %
3		HFIP	0 %




Table 4.

Entry	1 (equiv.)	2 (equiv.)	Ligand	R ¹ /R ²	Yield
1	1	2.5		Ns/Bz	60 %
2	1	2.5		Boc/Bz	0 %
3	1	2.5		Piv/Bz	0 %
4	1	2.5		Ts/Ac	0 %
5	1	2.5		Ts/4-nitrophenyl	0 %
6	1	2.5		Boc/4-nitrophenyl	0 %
7	1	2.5		Boc/2,4-dinitrophenyl	0 %
8	1	2.5		Ts/Piv	83 %
9	1	2		Ts/Piv	81 %
10	1	2.5		Ts/Piv	73 %
11	1	2.5		Ts/Piv	72 %
12	1	2.5		Ts/Piv	81 %

Optimization on hexene 4a:




Table 5.

Entry	R ¹ /R ²	Fe Cat	Ligand	T °C	Yield
1	Ts/Piv	Fe(OAc) ₂		50 °C	Trace
2	Ts/Piv	Fe(OAc) ₂		70 °C	Trace
3	Ts/Piv	Fe(OTf) ₂		70 °C	37 %
4	Ts/Piv	Fe(OTf) ₂		50 °C	29 %
5	Ts/2,4-dichloro Bz	Fe(OTf) ₂		70 °C	36 %
6	Ts/Bz	Fe(OTf) ₂		70 °C	39 %
7	Ns/Bz	Fe(OTf) ₂		70 °C	31 %
8	Ts/Piv	Fe(OTf) ₂	Phenanth.	70 °C	Trace




Table 6.

Entry	R ¹ /R ²	Fe Cat	Ligand	Solvent	T °C	Yield
1	Ts/Piv	Fe(OTf) ₂		DCE	70 °C	25 %
2	Ts/Piv	Fe(OTf) ₂		MeOH	70 °C	Trace
3	Ts/Piv	Fe(OTf) ₂		THF	70 °C	0 %
4	Ts/Bz	Fe(OTf) ₂		MeNO ₂	70 °C	47 %
5	Ts/Bz	Fe(OTf) ₂		HFIP	70 °C	58 %
6	Ts/Bz	Fe(OTf) ₂		ACN / HFIP 4:1	70 °C	45 %
7	Ts/Bz	---	---	HFIP	70 °C	0 %
8	Ts/Bz	Fe(OTf) ₂		HFIP	60 °C	62 %
9	Ts/Bz	Fe(OTf) ₂		HFIP	50 °C	75 %










Table 7.

Entry	R ¹ /R ²	R ³	Fe Cat	Ligand	Solvent	Additive	T °C	Yield
1	Ts/Bz	Ph	Fe(OAc) ₂		ACN	NaOAc (1 equiv.)	70 °C	0 %
2	Ts/Piv	C ₄ H ₉	Fe(OTf) ₂		ACN	K ₂ CO ₃ (1 equiv.)	70 °C	0 %
3	Ts/Piv	C ₄ H ₉	Fe(OTf) ₂		ACN	NEt ₃ (1 equiv.)	70 °C	0 %
4	Ts/Bz	C ₄ H ₉	Fe(OTf) ₂		HFIP	NEt ₃ (10 mol %.)	r.t.	0 %
5	Ts/Bz	C ₄ H ₉	Fe(OTf) ₂		HFIP	Pyridine (10 mol %.)	r.t.	0 %

IV. Characterization of compounds


N-hydroxy-4-methylbenzenesulfonamide. Known compound²



white solid; m.p. 154-156 °C; ¹H NMR (MeOD, 500 MHz, ppm) δ = 7.82 (d, *J* = 8.5 Hz, 2H), 7.39 (d, *J* = 8.0 Hz, 2H), 2.44 (s, 3H); ¹³C NMR (MeOD, 125 MHz, ppm) δ = 145.4, 135.7, 130.4, 129.7, 21.5; IR (ν = cm⁻¹): 3386,

3221, 1595, 1319, 1157, 1089, 821, 725; HRMS (ESI): *m/z* calcd for C₇H₈NO₃S [M - H⁺] 186.0225, found 186.0226.


N-(benzoyloxy)-4-methylbenzenesulfonamide **1a**. Known compound³



White solid; 90 % Yield; m.p. 91-94 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 9.21 (s, 1H), 7.92 (d, *J* = 8.5 Hz, 2H), 7.83 (d, *J* = 8.5 Hz, 2H), 7.63 (t, *J* = 7.5 Hz, 1H), 7.46 (t, *J* = 8.0 Hz, 2H), 7.28 (d, *J* = 8.0 Hz, 2H), 2.40 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz, ppm)

δ = 165.1, 145.9, 134.7, 132.3, 130.1, 129.9, 129.0, 128.9, 125.9, 21.9; IR (ν = cm⁻¹): 3358, 3256, 3152, 1736, 1598, 1376, 1176, 1056, 815, 722; HRMS (ESI): *m/z* calcd for C₁₄H₁₂NO₄S [M - H⁺] 290.0487, found 290.0492.


4-methyl-*N*-(pivaloyloxy)benzenesulfonamide **1b**. Known compound⁴



White solid; 86 % Yield; m.p. 97-98 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 9.03 (s, 1H), 7.82 (d, *J* = 8.0 Hz, 2H), 7.35 (d, *J* = 8.0 Hz, 2H), 2.45 (s, 3H), 1.11 (s, 9H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 176.8, 145.9, 132.4, 130.0, 129.1, 38.4, 26.9, 21.9; IR (ν = cm⁻¹):

3134, 2982, 1754, 1358, 1170, 1101, 1086, 816, 752, 649; HRMS (ESI): *m/z* calcd for C₁₂H₁₈NO₄S [M + H⁺] 272.0957, found 272.0947.

2,6-bis(4,4-dimethyl-4,5-dihydrooxazol-2-yl)pyridine **L2**. Known compound⁵



Pale yellow to yellow solid; m.p. 130-132 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 8.18 (d, *J* = 7.5 Hz, 2H), 7.84 (t, *J* = 7.5 Hz, 1H), 4.21 (s, 4H), 1.39 (s, 12H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ =

² S.-M. Yang, B. Lagu, L. J. Wilson, *J. Org. Chem.* 2007, **72**, 8123.


³ L. Fan, J. Hao, J. Yu, X. Ma, J. Liu, X. Luan, *J. Am. Chem. Soc.* 2020, **142**, 6698.

⁴ A. Wang, J. Venditto, J. W. Darcy, M. H. Emmert, *Organometallics* 2017, **36**, 1259.

⁵ D.-F. Lu, C.-L. Zhu, Z.-X. Jia, H. Xu, *J. Am. Chem. Soc.* 2014, **136**, 13186.

161.0, 147.1, 137.3, 125.8, 79.9, 68.2, 28.6; IR ($\nu = \text{cm}^{-1}$): 3430, 2969, 2930, 2896, 1643, 1576, 1530, 1462, 1366, 1189, 1073, 975, 743; HRMS (ESI): m/z calcd for $\text{C}_{15}\text{H}_{20}\text{N}_3\text{O}_2$ [$\text{M} + \text{H}^+$] 274.1477, found 274.1545.


D-*cis*-styrene (**Z**)-2a-D. Known compound⁶



(**Z**)-2a-D

Colorless oil; ^1H NMR (CDCl_3 , 500 MHz, ppm) $\delta = 7.41$ (d, $J = 7.5$ Hz, 2H), 7.33 (t, $J = 7.5$ Hz, 2H), 7.27-7.25 (m, 1H), 6.71 (dt, $J = 2.5$ Hz, 10.5 Hz, 1H), 5.23 (d, $J = 10.5$ Hz, 1H).


D-*trans*-styrene (**E**)-2a-D. Known compound⁷



(**E**)-2a-D

Colorless oil; ^1H NMR (CDCl_3 , 500 MHz, ppm) $\delta = 7.41$ (d, $J = 7.0$ Hz, 2H), 7.33 (t, $J = 7.5$ Hz, 2H), 7.27-7.25 (m, 1H), 6.72 (d, $J = 17.5$ Hz, 1H), 5.73 (d, $J = 17.5$ Hz, 1H).

2-phenyl-1-tosylaziridine **3a**. Known compound.⁸




3a

White solid; m = 62 mg, 83 % Yield; m.p. 88-89 °C; ^1H NMR (CDCl_3 , 500 MHz, ppm) $\delta = 7.87$ (d, $J = 8.5$ Hz, 2H), 7.33 (d, $J = 8.5$ Hz, 2H), 7.30-7.25 (m, 3H), 7.24-7.19 (m, 2H), 3.78 (dd, $J = 4.5$ Hz, 7 Hz, 1H), 2.99 (d, $J = 7.5$ Hz, 1H), 2.43 (s, 3H), 2.39 (d, $J = 5$ Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz, ppm) $\delta = 144.8, 135.2, 129.9, 128.7, 128.4, 128.1, 126.7, 41.2, 36.0, 21.8$; IR ($\nu = \text{cm}^{-1}$): 3007, 2921, 1596, 1459, 1322, 1158, 1095, 909, 817, 781; HRMS

(ESI): m/z calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2\text{S}$ [$\text{M} + \text{H}^+$] 274.0902, found 274.0889.

2-(naphthalene-2-yl)-1-tosylaziridine **3b**. Known compound⁹



3b

White solid; m = 68 mg, 77 % Yield; m.p. 128-130 °C; ^1H NMR (CDCl_3 , 500 MHz, ppm) $\delta = 7.90$ (d, $J = 8.0$ Hz, 2H), 7.81-7.75 (m, 3H), 7.73 (s, 1H), 7.50-7.43 (m, 2H), 7.33 (d, $J = 8.0$ Hz, 2H), 7.26 (dd, $J = 2.0$ Hz, 8.5 Hz, 1H), 3.93 (dd, $J = 4.5$ Hz, 7.5 Hz, 1H), 3.07 (d, $J = 7.5$ Hz, 1H), 2.50 (d, $J = 4.5$ Hz, 1H), 2.42 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz, ppm) $\delta = 144.8, 135.2, 133.3, 133.2, 132.6, 129.9, 128.6, 128.1, 127.9, 127.8,$

⁶ L. T. Ball, G. C. Lloyd-Jones, C. A. Russell, *Chem. Eur. J.* 2012, **18**, 2931.


⁷ R. Robiette, J. Pospisil, *Eur. J. Org. Chem.* 2013, 836.

⁸ E. Martinand-Lurin, R. Gruber, P. Retailleau, P. Fleurat-Lessard, P. Dauban, *J. Org. Chem.* 2015, **80**, 1414.

⁹ G.-Y. Gao, J. D. Harden, X. P. Zhang, *Org. Lett.* 2005, **7**, 3191.


126.6, 126.4, 126.3, 123.8, 41.4, 36.1, 21.8; IR ($\nu = \text{cm}^{-1}$): 3057, 2924, 2851, 1598, 1314, 1157, 1094, 926, 860, 820, 723; HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{18}\text{NO}_2\text{S}$ [$\text{M} + \text{H}^+$] 324.1058, found 324.1044.

2-(2-chlorophenyl)-1-tosylaziridine **3c**. Known compound¹⁰




White solid; $m = 74$ mg, 87 % Yield; m.p. 92-93 °C; ^1H NMR (CDCl_3 , 500 MHz, ppm) $\delta = 7.90$ (d, $J = 7.5$ Hz, 2H), 7.40-7.30 (m, 3H), 7.24-7.14 (m, 3H), 4.05 (brs, 1H), 3.04 (d, $J = 7.0$ Hz, 1H), 2.45 (s, 3H), 2.30 (d, $J = 4.0$ Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz, ppm) $\delta = 145.0, 134.7, 133.9, 133.2, 129.9, 129.4, 129.3, 128.3, 127.6, 127.1, 39.1, 35.8, 21.8$; IR ($\nu = \text{cm}^{-1}$): 2922, 1596, 1324, 1162, 1094, 907, 767, 731; HRMS (ESI): m/z calcd for $\text{C}_{15}\text{H}_{15}\text{ClNO}_2\text{S}$ [$\text{M} + \text{H}^+$] 308.0512, found 308.0499.

2-(3-chlorophenyl)-1-tosylaziridine **3d**. Known compound⁴



White solid; $m = 72$ mg, 85 % Yield; m.p. 59-60 °C; ^1H NMR (CDCl_3 , 500 MHz, ppm) $\delta = 7.86$ (d, $J = 8.5$ Hz, 2H), 7.34 (d, $J = 8.5$ Hz, 2H), 7.27-7.20 (m, 2H), 7.18 (brs, 1H), 7.14-7.10 (m, 1H), 3.73 (dd, $J = 4.5$ Hz, 7.0 Hz, 1H), 2.97 (d, $J = 7.0$ Hz, 1H), 2.44 (s, 3H), 2.34 (d, $J = 4.0$ Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz, ppm) $\delta = 145.0, 137.4, 134.9, 134.7, 129.9, 128.6, 128.1, 126.7, 125.0, 40.2, 36.2, 21.8$; IR ($\nu = \text{cm}^{-1}$): 3068, 2922, 1605, 1320, 1310, 1156, 1092, 921, 837, 780, 727; HRMS (ESI): m/z calcd for $\text{C}_{15}\text{H}_{15}\text{ClNO}_2\text{S}$ [$\text{M} + \text{H}^+$] 308.0512, found 308.0499.

2-(4-chlorophenyl)-1-tosylaziridine **3e**. Known compound¹¹




White solid; $m = 74$ mg, 87 % Yield; m.p. 112-113 °C; ^1H NMR (CDCl_3 , 500 MHz, ppm) $\delta = 7.85$ (d, $J = 8.5$ Hz, 2H), 7.33 (d, $J = 8.5$ Hz, 2H), 7.28-7.24 (m, 2H), 7.15 (d, $J = 8.0$ Hz, 2H), 3.73 (dd, $J = 4.0$ Hz, 7.0 Hz, 1H), 2.98 (d, $J = 7.5$ Hz, 1H), 2.44 (s, 3H), 2.34 (d, $J = 4.5$ Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz, ppm) $\delta = 144.9, 135.0, 134.4, 133.8, 130.0, 128.9, 128.1, 128.0, 40.4, 36.2, 21.8$; IR ($\nu = \text{cm}^{-1}$): 2922, 1596, 1494, 1322, 1160, 1093, 912, 819, 732; HRMS (ESI): m/z calcd for $\text{C}_{15}\text{H}_{15}\text{ClNO}_2\text{S}$ [$\text{M} + \text{H}^+$] 308.0512, found 308.0499.

¹⁰ Craig II, R. A.; O'Connor, N. R.; Goldberg, A. F. G.; Stoltz, B. M. *Chem. Eur. J.* **2014**, *20*, 4806.


¹¹ Hsueh, N.; Clarkson, G. J.; Shipman, M. *Org. Lett.* **2015**, *17*, 3632.

2-(4-fluorophenyl)-1-tosylaziridine **3f**. Known compound³




White oily paste; m = 67 mg, 84 % Yield; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.86 (d, *J* = 8.5 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.21-7.16 (m, 2H), 6.97 (t, *J* = 8.5 Hz, 2H), 3.75 (dd, *J* = 4.5 Hz, 7.5 Hz, 1H), 2.96 (d, *J* = 7.0 Hz, 1H), 2.43 (s, 3H), 2.34 (d, *J* = 4.5 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 162.8 (d, *J* = 245 Hz), 144.9, 135.1, 131.0 (d, *J* = 3.6 Hz), 129.9, 128.4 (d, *J* = 8.1 Hz), 128.1, 115.7 (d, *J* = 21.6 Hz), 40.4, 36.1, 21.8; IR (ν = cm⁻¹): 2924, 2849, 1597, 1515, 1338, 1158, 834, 816, 734; HRMS (ESI): *m/z* calcd for C₁₅H₁₅FNO₂S [M + H⁺] 292.0808, found 292.0794.

2-(4-bromophenyl)-1-tosylaziridine **3g**. Known compound³




Isolated with a small amount of the debrominated aziridine. White solid; m = 74.5 mg, 77 % Yield; m.p. 120-122 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.85 (d, *J* = 8.0 Hz, 2H), 7.42 (d, *J* = 8.5 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.09 (d, *J* = 8.5 Hz, 2H), 3.72 (dd, *J* = 4.5 Hz, 7.5 Hz 1H), 2.98 (d, *J* = 7.5 Hz, 1H), 2.44 (s, 3H), 2.34 (d, *J* = 4.5 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 145.0, 134.9, 134.3, 131.9, 129.9, 128.3, 128.1, 122.4, 40.5, 36.2, 21.8; IR (ν = cm⁻¹): 2922, 1596, 1489, 1319, 1160, 1093, 909, 821, 729; HRMS (ESI): *m/z* calcd for C₁₅H₁₅BrNO₂S [M + H⁺] 352.0007, found 351.9992.

1-tosyl-2-(4-(trifluoromethyl)phenyl)aziridine **3h**. Known compound³




White solid; m = 65 mg, 70 % Yield; m.p. 79-82 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.87 (d, *J* = 8.0 Hz, 2H), 7.55 (d, *J* = 8.5 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 4H), 3.81 (dd, *J* = 4.5 Hz, 7 Hz, 1H), 3.02 (d, *J* = 7.0 Hz, 1H), 2.44 (s, 3H), 2.37 (d, *J* = 4.5 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 145.1, 139.4, 134.9, 130.7 (q, *J* = 32.4 Hz), 130.0, 128.1, 127.1, 125.7 (d, *J* = 3.6 Hz), 124.0 (d, *J* = 270.4 Hz), 40.3, 36.3, 21.8; IR (ν = cm⁻¹): 2921, 2851, 1622, 1320, 1160, 1120, 1066, 918, 819, 713; HRMS (ESI): *m/z* calcd for C₁₆H₁₅F₃NO₂S [M + H⁺] 342.0776, found 342.0761.

4-(1-tosylaziridin-2-yl)phenyl acetate **3i**. Known compound³




White solid; m = 71 mg, 78 % Yield; m.p. 96-100 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.86 (d, *J* = 8.0 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.22 (d, *J* = 8.5 Hz, 2H), 7.01 (d, *J* = 8.5 Hz, 2H), 3.75 (dd, *J* = 4.5 Hz, 7.5 Hz, 1H), 2.98 (d, *J* = 7.0, 1H), 2.43 (s, 3H), 2.35 (d, *J* = 4.5 Hz, 1H), 2.27 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 169.5, 150.7, 144.9, 135.1, 132.8, 129.9, 128.1, 127.8, 121.9, 40.6, 36.1, 21.8, 21.2; IR (ν = cm⁻¹): 2921, 2849, 1759, 1510, 1320, 1220, 1191, 1156, 1092, 911, 815, 708; HRMS (ESI): *m/z* calcd for C₁₇H₁₆NO₄S [M - H⁺] 330.0800, found 330.0808.

2-(4-nitrophenyl)-1-tosylaziridine **3j**. Known compound¹²



White/yellowish solid; m = 52 mg, 59 % Yield; m.p. 108-112 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 8.15 (d, *J* = 9.0 Hz, 2H), 7.87 (d, *J* = 8.5 Hz, 2H), 7.40 (d, *J* = 8.5 Hz, 2H), 7.35 (d, *J* = 8.5 Hz, 2H), 3.84 (dd, *J* = 4.5 Hz, 7.5 Hz, 1H), 3.05 (d, *J* = 7.5 Hz, 1H), 2.44 (s, 3H), 2.37 (d, *J* = 4.0 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 148.0, 145.3, 142.7, 134.6, 130.0, 128.1, 127.6, 124.0, 39.8, 36.7, 21.8; IR (ν = cm⁻¹): 3112, 3087, 2918, 2849, 1600, 1510, 1345, 1323, 1162, 898, 854, 724; HRMS (ESI): *m/z* calcd for C₁₅H₁₄N₂O₄ClS [M + Cl⁻] 353.0363, found 353.0369.

4-(1-tosylaziridine-2-yl)benzotrile **3k**. Known compound¹³




White solid; m = 32 mg, 39 % Yield; m.p. 82-86 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.85 (d, *J* = 8.0 Hz, 2H), 7.58 (d, *J* = 8.5 Hz, 2H), 7.34 (dd, *J* = 2.5 Hz, 8.5 Hz, 4H), 3.79 (dd, *J* = 4.0 Hz, 7.0 Hz, 1H), 3.01 (d, *J* = 7.0 Hz, 1H), 2.44 (s, 3H), 2.34 (d, *J* = 4.0 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 145.2, 140.7, 134.7, 132.5, 130.0, 128.1, 127.4, 118.5, 112.3, 40.0, 36.6, 21.8; IR (ν = cm⁻¹): 2927, 2849, 1597, 1453, 1320, 1162, 1094, 917, 815, 713; HRMS (ESI): *m/z* calcd for C₁₆H₁₅N₂O₂S [M + H⁺] 299.0854, found 299.0841.

¹² D. A. Evans, M. T. Bilodeau, M. M. Faul, *J. Am. Chem. Soc.* 1994, **116**, 2742.

¹³ K. Kiyokawa, T. Kosaka, S. Minakata, *Org. Lett.* 2013, **15**, 4858.

2-(1-tosylaziridin-2-yl)pyridine **3l**. Known compound⁴




This compound was prepared using aziridination procedure A with Fe(OTf)₂ (10 mol %) instead of Fe(OAc)₂ (10 mol %).

Yellow/orange oil; m = 20 mg, 27 % Yield; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 8.52 (d, *J* = 5.0 Hz, 1H), 7.87 (d, *J* = 8.5 Hz, 2H), 7.63 (td, *J* = 2 Hz, 7.5 Hz, 1H), 7.32 (d, *J* = 8.5 Hz, 2H), 7.27 (d, *J* = 7.5 Hz, 1H), 7.22-7.18 (m, 1H), 3.90 (dd, *J* = 4 Hz, 7 Hz, 1H), 2.97 (d, *J* = 7.0 Hz, 1H), 2.66 (d, *J* = 4.5 Hz,

1H), 2.43 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 154.5, 149.8, 144.9, 136.9, 134.8, 129.9, 128.3, 123.4, 121.9, 41.5, 35.1, 21.8; IR (ν = cm⁻¹): 2923, 1594, 1324, 1161, 1092, 914, 803, 714; HRMS (ESI): *m/z* calcd for C₁₄H₁₅N₂O₂S [M + H⁺] 275.0854, found 275.0841.


2-(*o*-tolyl)-1-tosylaziridine **3m**. Known compound¹⁴



White solid; m = 66 mg, 83 % Yield; m.p. 78-80 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.91 (d, *J* = 8.0 Hz, 2H), 7.35 (d, *J* = 8.0 Hz, 2H), 7.21-7.09 (m, 4H), 3.87 (dd, *J* = 5 Hz, 7.5 Hz, 1H), 2.99 (d, *J* = 7.0 Hz, 1H), 2.45 (s, 3H), 2.39 (s, 3H), 2.32 (d, *J* = 4.5 Hz, 1H); ¹³C NMR (CDCl₃, 126 MHz, ppm) δ = 144.8, 136.8, 135.0, 133.3, 130.1, 129.9, 128.2, 128.1, 126.2, 126.0, 39.6, 35.1, 21.8, 19.2; IR (ν = cm⁻¹): 3057, 2918, 2845, 1597, 1460, 1321, 1161, 908, 773, 712;

HRMS (ESI): *m/z* calcd for C₁₆H₁₈NO₂S [M + H⁺] 288.1058, found 288.1045.

2-(*m*-tolyl)-1-tosylaziridine **3n**. Known compound³




White solid; m = 66 mg, 84 % Yield; m.p. 64-66 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.88 (d, *J* = 8.5 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.18 (t, *J* = 8.0 Hz, 1H), 7.08 (d, *J* = 7.5 Hz, 1H), 7.04-7.00 (m, 2H), 3.75 (dd, *J* = 4.5 Hz, 7.5 Hz, 1H), 2.96 (d, *J* = 7.0 Hz, 1H), 2.43 (s, 3H), 2.38 (d, *J* = 4.0 Hz, 1H), 2.30 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.7, 138.4, 135.1, 135.0, 129.9, 129.2, 128.6, 128.1, 127.2, 123.8, 41.1, 36.0, 21.8, 21.4; IR (ν = cm⁻¹): 3081, 2922 1596, 1453, 1317, 1156, 1091, 935, 863, 806, 788, 720; HRMS (ESI): *m/z*

calcd for C₁₆H₁₈NO₂S [M + H⁺] 288.1058, found 288.1037.

¹⁴ C.-Y. Huang, A. G. Doyle, *J. Am. Chem. Soc.* 2012, **134**, 9541.


2-(*p*-tolyl)-1-tosylaziridine **3o**. Known compound³



White solid; m = 58 mg, 73 % Yield; m.p. 133-134 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.86 (d, *J* = 8.0 Hz, 2H), 7.32 (d, *J* = 8.5 Hz, 2H), 7.1 (s, 4H), 3.74 (dd, *J* = 4.0 Hz, 1H), 2.97 (d, *J* = 7.0 Hz, 1H), 2.43 (s, 3H), 2.38 (d, *J* = 4.5 Hz, 1H), 2.31 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.7, 138.3, 135.3, 132.2, 129.9, 129.4, 128.1, 126.6, 41.2, 35.9, 21.8, 21.3; IR (ν = cm⁻¹): 2920, 2851, 1595, 1518, 1319, 1159, 1093, 912, 815;

HRMS (ESI): *m/z* calcd for C₁₆H₁₈NO₂S [M + H⁺] 288.1058, found 288.1043.


2-(2-methoxyphenyl)-1-tosylaziridine **3p**. Known compound¹⁵



White solid; m = 24 mg, 27 % Yield; m.p. 112-114 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.89 (d, *J* = 8.5 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.25-7.21 (m, 1H), 7.08 (dd, *J* = 2 Hz, 8 Hz, 1H), 6.89-6.79 (m, 2H), 4.07 (dd, *J* = 4.5 Hz, 7.5 Hz, 1H), 3.79 (s, 3H), 2.98 (d, *J* = 7.5 Hz, 1H), 2.44 (s, 3H), 2.33 (d, *J* = 4.5 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 158.2, 144.6, 135.2, 129.8, 129.3, 128.2, 126.7, 123.6, 120.7, 110.2, 55.5, 37.5, 35.3, 21.8; IR (ν =

cm⁻¹): 3003, 2924, 2844, 1602, 1494, 1316, 1249, 1162, 910, 763, 715; HRMS (ESI): *m/z* calcd for C₁₆H₁₈NO₃S [M + H⁺] 304.1007, found 304.0993.

2,3-diphenyl-1-tosylaziridine **3q**. Known compound.¹⁶



This compound was prepared using aziridination procedure A with a slight modification: substrate **1a** (0.4 mmol), Fe(OAc)₂ (5 mol %) and phenanthroline (10 mol %).


White solid; m = 70 mg, 50 % Yield; m.p. 136-138 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.63 (d, *J* = 8.5 Hz, 2H), 7.44-7.39 (m, 4H), 7.38-7.32 (m, 6H), 7.20 (d, *J* = 8.0 Hz, 2H), 4.26 (s, 2H), 2.39 (s, 3H); ¹³C NMR

(CDCl₃, 125 MHz, ppm) δ = 144.1, 137.1, 133.1, 129.5, 128.8, 128.6, 128.4, 127.7, 50.5, 21.7; IR (ν = cm⁻¹): 3063, 2851, 1451, 1321, 1158, 903, 765; HRMS (ESI): *m/z* calcd for C₂₁H₁₈NO₂S [M - H⁺] 348.1058, found 348.1066.

¹⁵ P.-J. Yang, L. Qi, Z. Liu, G. Yang, Z. Chai, *J. Am. Chem. Soc.* 2018, **140**, 17211.

¹⁶ R. Vyas, G.-Y. Gao, J. D. Harden, X. P. Zhang, *Org. Lett.* 2004, **6**, 1907.


2-butyl-1-tosylaziridine **5a**. Known compound⁸



5a

Colorless oil; m = 38 mg, 75 % Yield; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.82 (d, *J* = 8.5 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 2.75-2.68 (m, 1H), 2.62 (d, *J* = 6.5 Hz, 1H), 2.44 (s, 3H), 2.05 (d, *J* = 4.5 Hz, 1H), 1.57-1.49 (m, 1H), 1.38-1.32 (m, 1H), 1.27-1.20 (m, 4H), 0.81 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.5, 135.4, 129.7, 128.1, 40.5, 33.9, 31.1, 29.0, 22.2, 21.7, 13.9; IR (ν = cm⁻¹): 2958, 2930, 2861, 1598, 1457, 1323, 1160, 1091, 816, 714; HRMS (ESI): *m/z* calcd for C₁₃H₂₀NO₂S [M + H⁺] 254.1215, found 254.1203.


2-pentyl-1-tosylaziridine **5b**. Known compound¹⁷



5b

Colorless oil; m = 40 mg, 75 % Yield; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.82 (d, *J* = 8.0 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 2.74-2.67 (m, 1H), 2.64 (d, *J* = 7.0 Hz, 1H), 2.44 (s, 3H), 2.06 (d, *J* = 4.5 Hz, 1H), 1.57-1.48 (m, 1H), 1.35-1.27 (m, 1H), 1.23-1.16 (m, 6H), 0.82 (t, *J* = 6.5 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.6, 135.3, 129.8, 128.1, 40.7, 33.9, 31.4, 31.3, 26.6, 22.6, 21.8, 14.0; IR (ν = cm⁻¹): 2927, 2853, 1598, 1459, 1326, 1162, 1093, 930, 816, 715; HRMS (ESI): *m/z* calcd for C₁₄H₂₂NO₂S [M + H⁺] 268.1371, found 268.1365.

2-hexyl-1-tosylaziridine **5c**. Known compound¹⁸




5c

Colorless oil; m = 41 mg, 73 % Yield; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.83 (d, *J* = 8.0 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 2.74-2.68 (m, 1H), 2.64 (d, *J* = 7.0 Hz, 1H), 2.44 (s, 3H), 2.06 (d, *J* = 4.5 Hz, 1H), 1.57-1.50 (m, 1H), 1.34-1.29 (m, 1H), 1.23-1.13 (m, 8H), 0.85 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.6, 135.3, 129.7, 128.1, 40.6, 33.9, 31.7, 31.5, 28.8, 26.9, 22.6, 21.8, 14.2; IR (ν = cm⁻¹): 2927, 2856, 1598, 1458, 1324, 1161, 1092, 714; HRMS (ESI): *m/z* calcd for C₁₅H₂₄NO₂S [M + H⁺] 282.1528, found 282.1515.

¹⁷ D. M. Hodgson, M. J. Flemong, S. J. Stanway, *Org. Lett.* 2005, **15**, 3295.

¹⁸ I. Saikia, B. Kashyap, P. Phukan, *Chem. Commun.*, 2011, **47**, 2967.


2-nonyl-1-tosylaziridine **5d**. Known compound¹⁹



5d

Colorless oil; m = 44.5 mg, 69 % Yield; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.83 (d, *J* = 8.0 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 2.74-2.68 (m, 1H), 2.64 (d, *J* = 7.0 Hz, 1H), 2.44 (s, 3H), 2.05 (d, *J* = 4.5 Hz, 1H), 1.56-1.50 (m, 1H), 1.34-1.26 (m, 3H), 1.25-1.14 (m, 12H), 0.88 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.5, 135.3, 129.7, 128.1, 40.7, 33.9, 32.0, 31.4, 29.5, 29.4, 29.2, 26.9, 22.8, 21.8, 14.3; IR (ν = cm⁻¹): 2956, 2929, 2854, 1597, 1459, 1325, 1162, 1092, 925, 816, 715; HRMS (ESI): *m/z* calcd for C₁₈H₃₀NO₂S [M + H⁺] 324.1997, found 324.1991.


2-(4-bromobutyl)-1-tosylaziridine **5e**.



5e

Colorless oil; m = 41.5 mg, 62 % Yield; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.83 (d, *J* = 8.5 Hz, 2H), 7.35 (d, *J* = 8.5 Hz, 2H), 3.31-3.26 (m, 2H), 2.74-2.68 (m, 1H), 2.65 (d, *J* = 7.0 Hz, 1H), 2.45 (s, 3H), 2.07 (d, *J* = 4.5 Hz, 1H), 1.81-1.74 (m, 2H), 1.67-1.60 (m, 1H), 1.41-1.27 (m, 3H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.8, 135.1, 129.8, 128.1, 40.1, 33.9, 33.4, 32.0, 30.6, 25.6, 21.8; IR (ν = cm⁻¹): 3052, 2928, 2849, 1597, 1457, 1325, 1160, 1092, 915, 817, 768; HRMS (ESI): *m/z* calcd for C₁₃H₁₉BrNO₂S [M + H⁺] 332.0320, found 332.0314.

2-isobutyl-1-tosylaziridine **5f**. Known compound²⁰




5f

Colorless oil; m = 43 mg, 84 % Yield; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.82 (d, *J* = 8.5 Hz, 2H), 7.33 (d, *J* = 8.5 Hz, 2H), 2.82-2.74 (m, 1H), 2.62 (d, *J* = 7.5 Hz, 1H), 2.44 (s, 3H), 2.02 (d, *J* = 4.5 Hz, 1H), 1.63-1.56 (m, 1H), 1.37-1.29 (m, 2H), 0.88 (d, *J* = 2.5 Hz, 3H), 0.87 (d, *J* = 2.5 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.5, 135.3, 129.8, 128.1, 40.5, 39.2, 34.2, 26.9, 22.9, 22.0, 21.8; IR (ν = cm⁻¹): 2958, 2929, 2873, 1598, 1468, 1323, 1159, 1092, 870, 714; HRMS (ESI): *m/z* calcd for C₁₃H₂₀NO₂S [M + H⁺] 254.1215, found 254.1211.

¹⁹ G. Kumaraswamy, K. Ankamma, A. Pitchaiah, *J. Org. Chem.* 2007, **72**, 9822.

²⁰ G. P. Y. Kok, H. Yang, M. W. Wong, Y. Zhao, *Org. Lett.* 2018, **20**, 5112.

2-cyclohexyl-1-tosylaziridine **5g**. Known compound²¹




5g

Colorless oil; m = 33 mg, 59 % Yield; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.82 (d, *J* = 8.0 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 2.59 (d, *J* = 7.0 Hz, 1H), 2.55-2.50 (m, 1H), 2.44 (s, 3H), 2.10 (d, *J* = 5.0 Hz, 1H), 1.72-1.66 (m, 1H), 1.66-1.59 (m, 3H), 1.53-1.47 (m, 1H), 1.17-0.99 (m, 5H), 0.96-0.87 (m, 1H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.5, 135.2, 129.7, 128.2, 45.3, 39.5, 32.8, 30.3, 29.7, 26.1, 25.7, 25.5, 21.8; IR (ν = cm⁻¹): 2926, 2852, 1598, 1450, 1323, 1160, 887, 720; HRMS (ESI): *m/z* calcd for C₁₅H₂₂NO₂S [M + H⁺]

280.1371, found 280.1367.

2-benzyl-1-tosylaziridine **5h**. Known compound¹⁴




5h

Colorless/White oily solid; m = 23 mg, 40 % Yield; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.69 (d, *J* = 8.0 Hz, 2H), 7.21 (d, *J* = 8.5 Hz, 2H), 7.19-7.12 (m, 3H), 7.09-7.01 (m, 2H), 2.99-2.90 (m, 1H), 2.81 (dd, *J* = 5.5 Hz, 14.5 Hz, 1H), 2.74-2.66 (m, 2H), 2.42 (s, 3H), 2.16 (d, *J* = 4.5 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.4, 137.1, 134.9, 129.7, 128.8, 128.6, 128.0, 126.6, 41.3, 37.6, 33.0, 21.8; IR (ν = cm⁻¹): 3027, 2922, 2854, 1598, 1497,

1455, 1323, 1161, 714; HRMS (ESI): *m/z* calcd for C₁₆H₁₇NO₂SNa [M + Na⁺] 310.0878, found 310.0873.

2-phenyl-1-tosylaziridine-3-*d* (*cis*)-**3a-D**. Known compound²²



(*cis*)-**3a-D**


White solid; 81 % Yield (*cis/trans* ratio = 75:25); m.p. 84-85 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.87 (d, *J* = 8.0 Hz, 2H), 7.33 (d, *J* = 8.5 Hz, 2H), 7.30-7.27 (m, 3H), 7.24-7.20 (m, 2H), 3.78 (d, *J* = 7.0 Hz, 1H), 2.97 (d, *J* = 7.5 Hz, 1H, H-*cis*), 2.43 (s, 3H), [minor 2.38 (d, *J* = 4.5 Hz, 1H, H-*trans*)]; ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.9, 135.2, 135.1, 130.0, 128.8, 128.5,

128.1, 126.8, 41.2, 35.9 (t, *J* = 27 Hz), 21.9.

²¹ J. M. Concellon, H. Rodriguez-Solla, C. Simal, *Org. Lett.* 2008, **10**, 4457.

²² V. K. Aggarwal, E. Alonso, M. Ferrara, S. E. Spey, *J. Org. Chem.* 2002, **67**, 2335.

2-phenyl-1-tosylaziridine-3-*d* (*trans*)-**3a-D**.



White solid; 78 % Yield (cis/trans ratio = 25:75); m.p. 84-85 °C; ¹H NMR (CDCl₃, 500 MHz, ppm) δ = 7.87 (d, *J* = 8.5 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.30-7.27 (m, 3H), 7.24-7.20 (m, 2H), 3.77 (d, *J* = 5.0 Hz, 1H), [minor 2.97 (d, *J* = 7.5 Hz, 1H), H-cis), 2.43 (s, 3H), 2.38 (d, *J* = 4.5 Hz, 1H, H-trans); ¹³C NMR (CDCl₃, 125 MHz, ppm) δ = 144.8, 135.2, 135.1, 129.9, 128.7, 128.4, 128.1, 126.7, 41.1, 35.8

(t, *J* = 25.7 Hz), 21.8.

V. Copy of ^1H and ^{13}C NMR spectra

